Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 12/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085066 | 0.90 | BDKRB1 (0.42) | BDKRB1KDM4E | |
| SCHEMBL4081206 | 0.89 | ALDH1A1 (0.37) | BDKRB1KDM4EALDH1A1AVPR1BBMP1 | |
| SCHEMBL4093356 | 0.88 | BDKRB1 (0.38) | BDKRB1ALDH1A1 | |
| SCHEMBL4091715 | 0.87 | BDKRB1 (0.37) | BDKRB1AVPR1BMMP1BMP1MMP8 | |
| SCHEMBL4080320 | 0.87 | BDKRB1 (0.37) | BDKRB1ALDH1A1 | |
| SCHEMBL4081145 | 0.86 | BDKRB1 (0.35) | MEN1KMT2ABDKRB1KDM4EAVPR1B | |
| SCHEMBL4080766 | 0.86 | BDKRB1 (0.38) | BDKRB1AVPR1B | |
| SCHEMBL4094722 | 0.86 | MAPT (0.43) | MEN1KMT2ABDKRB1KDM4EALDH1A1 | |
| SCHEMBL4091775 | 0.86 | ADRA2C (0.36) | MEN1KMT2ABDKRB1ALDH1A1NPSR1 | |
| SCHEMBL4091422 | 0.86 | BDKRB1 (0.36) | BDKRB1ALDH1A1BMP1MMP8AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | claimed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | claimed |
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | MEN1 1412/4885KMT2A 1528/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.